Clinical trials: Platelet Reactivity
Coronary Artery Disease, Acute Coronary Syndrome
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Recently, two new oral P2Y12 antagonists have been approved for clinical use: prasugrel, a third generation thienopyridine, and ticagrelor, a first in class cyclopentyltriazolopyrimidine (CPTP).
- Trial name
- SWAP3 (NCT02016170)
- Testing
- Ticagrelor 180mg, Prasugrel 10mg, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Florida
PRU, miRNA
The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment
For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines)…
- Trial name
- NCT02101437
- Testing
- miRNA within 24hr, miRNA after 1 week, miRNA after 1 month
- Where
- Taiwan
- Volunteers
- 175 people
- Sponsor
- Taipei City Hospital
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski